IP Library Granted Patent US 8,921,064
Granted Patent B2
US 8,921,064 · App. 13/085,793 · Granted Dec 30, 2014

Method for purifying urate oxidase tetramers and octamers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,921,064
App. No.
13/085,793
Granted
Dec 30, 2014
Kind
B2
Abstract

A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates.

Claims (6)

1. A method for purifying urate oxidase (uricase) tetramers and octamers, the method comprising

(a) separating a uricase solution comprising uricase aggregates larger than octamers, uricase tetramers, and uricase octamers into fractions,

(b) detecting said aggregates larger than octamers in said fractions by measuring light scattering; and

(c) excluding fraction(s) containing said aggregates larger than octamers as detected in (b), thereby producing purified uricase tetramers and octamers.

2. The method of claim 1 , wherein said separating is accomplished by a method selected from the group consisting of ion-exchange chromatography, size-exclusion chromatography, and ultrafiltration.

3. The method of claim 1 , wherein said purified uricase contains no more than 2% of said aggregates larger than octamers.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS USA, INC.
Reel/Frame 065178/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2023
From: HORIZON PHARMA RHEUMATOLOGY LLC
To: HORIZON THERAPEUTICS USA, INC.
Reel/Frame 062294/0205 →
CHANGE OF NAME Recorded Nov 18, 2016
From: CREALTA PHARMACEUTICALS LLC
To: HORIZON PHARMA USA RHEUMATOLOGY LLC
Reel/Frame 040648/0361 →
CHANGE OF NAME Recorded Nov 18, 2016
From: HORIZON PHARMA USA RHEUMATOLOGY LLC
To: HORIZON PHARMA RHEUMATOLOGY LLC
Reel/Frame 040648/0367 →
PATENT SECURITY AGREEMENT Recorded Sep 16, 2016
From: HORIZON PHARMA RHEUMATOLOGY LLC (FORMERLY KNOWN AS CREALTA PHARMACEUTICALS LLC)
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 040059/0007 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2016
From: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0163 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2016
From: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0073 →
SECURITY INTEREST Recorded Aug 11, 2015
From: CREALTA PHARMACEUTICALS LLC
To: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
Reel/Frame 036300/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2015
From: MOUNTAIN VIEW PHARMACEUTICALS, INC.
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 036240/0827 →
SECURITY INTEREST Recorded Jul 21, 2015
From: CREALTA PHARMACEUTICALS LLC
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 036142/0931 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2013
From: HERSHFIELD, MICHAEL S.; KELLY, SUSAN J.
To: DUKE UNIVERSITY
Reel/Frame 030697/0797 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2013
From: SHERMAN, MERRY R.; SAIFER, MARK G.P.; WILLIAMS, L. DAVID
To: MOUNTAIN VIEW PHARMACEUTICALS, INC.
Reel/Frame 030697/0968 →